Sunday, July 6, 2025 7/6/2025

Mechanisms of DNA methylation signaling and dysregulation in colon cancer

Award Number: R01CA283463
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/02/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Mechanisms of DNA methylation signaling and dysregulation in colon cancer - PROJECT SUMMARY Colon cancer is a leading cause of cancer-related death for both men and women in the United States. Abnormal DNA methylation patterning is an epigenetic hallmark of colon and other cancer types and is a major contributing factor to genome instability and tumor suppressor gene silencing in this disease. Despite a deep appreciation of roles for DNA methylation in development and cancer, causal mechanisms that contribute to the evolution of DNA methylation abnormalities in colon and other cancer types, and consequences of this hallmark epigenetic remodeling on cancer development, remain poorly understood. This proposal seeks to address these fundamental knowledge gaps. Our preliminary data implicate protein ubiquitination as an essential post- translational modification (PTM) regulating the activity of DNMT1, the primary enzyme responsible for the epigenetic inheritance of DNA methylation patterns through mitotic cell divisions and a major target for epigenetic cancer therapy. Building from these data, studies in Aim 1 will characterize the ubiquitin signaling network that interfaces with DNA methylation inheritance. The therapeutic potential of targeting ubiquitin signaling regulators in this pathway will also be considered. In Aim 2, we will test a mechanistic hypothesis connecting overexpression of the E3 ubiquitin ligase UHRF1 to DNA methylation dysregulation and colon tumorigenesis. Aim 3 will investigate a non-canonical function for UHRF1 in the regulation of heterochromatic histone PTM signaling and its implications for DNA hypomethylation therapy. Overall, our studies at the interface of ubiquitin signaling and DNA methylation inheritance will reveal fundamental causes and consequences of abnormal DNA methylation signaling in colon cancer and identify novel approaches to enhance the efficacy of DNA hypomethylation therapy as a treatment strategy to manage this deadly disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $632,319 )
2025	2025	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Cause and Prevention Research	000	2	6/30/2025	NON-COMPETING CONTINUATION	$632,319
														Subtotal = $632,319

Issue Date FY: 2024 ( Subtotal = $632,319 )
2024	2024	VAN ANDEL RESEARCH INSTITUTE	333 BOSTWICK AVE NE	GRAND RAPIDS	MI	49503	KENT	USA	Cancer Cause and Prevention Research	000	1	7/2/2024	NEW	$632,319
														Subtotal = $632,319

Grand Total All Awards = $1,264,638

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanisms of DNA methylation signaling and dysregulation in colon cancer

Award Number: R01CA283463

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/02/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer